This article is more than 5 years old. Information may no longer be current.

DePuy Synthes introduces new cellular allograft for spine fusion

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DePuy Synthes, in collaboration with LifeNet Health, recently announced the introduction of ViviGen Cellular Bone Matrix, a differentiated cellular allograft for the repair or reconstruction of musculoskeletal defects.

ViviGen is a human cells, tissues, and cellular and tissue-based product that comprises cryopreserved live, viable cells within a cortical cancellous bone matrix and demineralized bone, delivering all of the properties required for bone formation. The new product is designed to maintain cell viability, resulting in an acceptable alternative to autograft, according to a company press release.

The product has been used in a number of spinal fusion surgeries since its initial availability, and the company plans to fully release the product in the U.S. in January 2015, according to the release.

Reference: www.depuysynthes.com.